— Why it moved
Why SNGX Stock Fizzled Today — May 27, 2026
The Ebola-vaccine pop happened before the bell; by the time the stock was flagged it was already rolling over.
What moved SNGX stock
Soligenix is a biotech with no approved product. It put out an update saying its ThermoVax thermostable filovirus vaccine work could be a starting point for a Bundibugyo Ebola vaccine — a platform "could apply" statement, about as early-stage as a catalyst gets. That hook doubled the stock in the premarket, and the whole move was spent by the bell.
The mechanics
A sub-dollar-turned-dollar biotech with a float under 10M shares and a $13M cap is the recipe for a violent premarket spike on outbreak news, and roughly 246M shares traded through it.
SNGX by the numbers
The alert window
The alert fired at 8:32 AM at $1.09 — after the premarket high near $1.30 had already come and gone. From there the stock managed only $1.13 at 9:45 AM: 73 minutes for 3.7%. A real-time reader was catching the tail end of a pop, not the pop.
How SNGX's move ended
It slid all day from that $1.13 print and closed at $0.87, 20.6% below the alert. There is no approved product behind the story, and the Ebola tie-in is aspirational — a platform statement, not a program with data. When the premarket high prints before the alert, the day session isn't a second chance at the move; it's the distribution of it.